2016
Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer
Fu Y, Biglia N, Wang Z, Shen Y, Risch HA, Lu L, Canuto EM, Jia W, Katsaros D, Yu H. Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer. Gynecologic Oncology 2016, 143: 642-649. PMID: 27667152, PMCID: PMC5507336, DOI: 10.1016/j.ygyno.2016.09.021.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdenocarcinoma, Clear CellAdultAgedAged, 80 and overCarcinoma, EndometrioidCarcinoma, Ovarian EpithelialHumansMiddle AgedNeoplasm GradingNeoplasm StagingNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisProportional Hazards ModelsReverse Transcriptase Polymerase Chain ReactionRNA, Long NoncodingYoung AdultConceptsEpithelial ovarian cancerOvarian cancerStage diseasePatient survivalGrade tumorsASAP1-IT1Survival associationsLong non-coding RNAsCox proportional hazards regression modelPrimary epithelial ovarian cancerProportional hazards regression modelsTumor samplesFresh frozen tumor samplesHigh expressionEarly-stage diseaseFavorable overall survivalLate-stage diseaseHazards regression modelsLow-grade tumorsHigh-grade tumorsOvarian cancer progressionNon-coding RNAsImportant biological actionsOverall survivalPoor prognosis
2008
TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival
Mu L, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Yu H. TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. British Journal Of Cancer 2008, 99: 1357-1363. PMID: 18827819, PMCID: PMC2570529, DOI: 10.1038/sj.bjc.6604689.Peer-Reviewed Original ResearchConceptsHigher TGF-β1TGF-β1 genotypesTGF-β1T genotypeHazard ratioBreast cancerBreast tumorsProportional hazards regression analysisLower TGF-β1Early-stage diseaseHazards regression analysisBreast cancer patientsLate-stage diseaseShorter overall survivalFresh tumor samplesTGF-β1 concentrationsBreast cancer progressionClinical characteristicsIGFBP-3Overall survivalDisease recurrenceReceptor statusPatient survivalSurvival outcomesDisease stage
2006
Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer
Lu L, Katsaros D, Wiley A, de la Longrais I, Puopolo M, Schwartz P, Yu H. Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Gynecologic Oncology 2006, 103: 990-995. PMID: 16859738, DOI: 10.1016/j.ygyno.2006.06.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overDisease ProgressionDNA PrimersFemaleGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor IIMiddle AgedNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPromoter Regions, GeneticReverse Transcriptase Polymerase Chain ReactionRNA, MessengerConceptsIGF-II promotersResidual tumorOvarian cancerIGF-II transcriptionNon-serous histologyInsulin-like growth factor IISmall residual tumorLarge residual tumorLate-stage diseaseEpithelial ovarian cancerOvarian cancer prognosisOvarian cancer progressionOvarian tumor samplesGrowth factor IIIGF-II geneOptimal debulkingQuantitative RT-PCRSerous histologyStage diseasePatient agePatient survivalDisease characteristicsDisease stageFetal growthIGF-II